Compare Google Inc (GOOG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Neurocrine Biosciences Inc — how do they compare? Google Inc trades at $347.87 (market cap $4.24T), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Google Inc is far larger — about 295.3× Neurocrine Biosciences Inc's market cap, and Google Inc pays a 0.26% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GOOG | NBIX | |
|---|---|---|
Market Cap | $4.24T | $14.36B |
Volume | 13,937,902 | 1,237,180 |
Sector | Media | Health |
52-Week High | $399.06 | $185.50 |
52-Week Low | $237.49 | $123.10 |
Typical Hold Time | 137 Days | 23 Days |
Enterprise Value | $4.13T | $14.37B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.37, up 0.81% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $9.11 significantly exceeding expectations. Revenue growth remains robust, rising from $282.8B in 2022 to $402.84B in 2025. Analyst consensus is overwhelmingly positive, with 87% recommending Buy and a price target of $435.24.
The outlook is favorable given earnings momentum and AI-driven cloud expansion, but risks include high capital expenditures leading to negative free cash flow projections and ongoing securities litigation. The stock offers substantial upside to the consensus target, though investors should weigh growth prospects against spending pressures and legal overhangs.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
